Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn

Table of Contents

November 01, 1993; Volume 21,Issue 6
  • You have access
    Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone.
    K Iwasaki, T Shiraga, K Nagase, Z Tozuka, K Noda, S Sakuma, T Fujitsu, K Shimatani, A Sato and M Fujioka
    Drug Metabolism and Disposition November 1993, 21 (6) 971-977;
  • You have access
    Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions.
    G Fabre, B Julian, B Saint-Aubert, H Joyeux and Y Berger
    Drug Metabolism and Disposition November 1993, 21 (6) 978-985;
  • You have access
    Kinetic analysis of the reaction of melphalan with water, phosphate, and glutathione.
    M G Bolton, J Hilton, K D Robertson, R T Streeper, O M Colvin and D A Noe
    Drug Metabolism and Disposition November 1993, 21 (6) 986-996;
  • You have access
    Effect of colchicine-specific Fab fragments on the hepatic clearance of colchicine.
    A Sabouraud, M Redureau, P Gires, M Martinet and J M Scherrmann
    Drug Metabolism and Disposition November 1993, 21 (6) 997-1002;
  • You have access
    Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human.
    R A Halpin, E H Ulm, A E Till, P H Kari, K P Vyas, D B Hunninghake and D E Duggan
    Drug Metabolism and Disposition November 1993, 21 (6) 1003-1011;
  • You have access
    Regioselective contribution of the cytochrome P-450 2D subfamily to propranolol metabolism in rat liver microsomes.
    Y Masubuchi, N Kagimoto, S Narimatsu, S Fujita and T Suzuki
    Drug Metabolism and Disposition November 1993, 21 (6) 1012-1016;
  • You have access
    Disposition of a new antiinfective agent 1,3-di(4-imidazolino-2-methoxyphenoxy)propane in male rats.
    I Bekersky, R J Puhl, G Hanson and S Mong
    Drug Metabolism and Disposition November 1993, 21 (6) 1017-1021;
  • You have access
    Disposition of salmeterol xinafoate in laboratory animals and humans.
    G R Manchee, A Barrow, S Kulkarni, E Palmer, J Oxford, P V Colthup, J G Maconochie and M H Tarbit
    Drug Metabolism and Disposition November 1993, 21 (6) 1022-1028;
  • You have access
    CYP1A1 specificity of Verlukast epoxidation in mice, rats, rhesus monkeys, and humans.
    S J Grossman, E G Herold, J M Drey, D W Alberts, D R Umbenhauer, D H Patrick, D Nicoll-Griffith, N Chauret and J A Yergey
    Drug Metabolism and Disposition November 1993, 21 (6) 1029-1036;
  • You have access
    Disposition of [14C]velnacrine maleate in rats, dogs, and humans.
    R G Turcan, D Hillbeck, T E Hartley, P J Gilbert, R A Coe, J A Troke and C W Vose
    Drug Metabolism and Disposition November 1993, 21 (6) 1037-1047;
  • You have access
    Characterization of cytochrome P-450 2B6 in human liver microsomes.
    M Mimura, T Baba, H Yamazaki, S Ohmori, Y Inui, F J Gonzalez, F P Guengerich and T Shimada
    Drug Metabolism and Disposition November 1993, 21 (6) 1048-1056;
  • You have access
    Distribution of 2-aminofluorene and p-aminobenzoic acid N-acetyltransferase activity in tissues of C57BL/6J rapid and B6.A-NatS slow acetylator congenic mice.
    J G Chung, G N Levy and W W Weber
    Drug Metabolism and Disposition November 1993, 21 (6) 1057-1063;
  • You have access
    Head injury and cytochrome P-450 enzymes. Differential effect on mRNA and protein expression in the Fischer-344 rat.
    S M Toler, A B Young, C J McClain, S I Shedlofsky, A M Bandyopadhyay and R A Blouin
    Drug Metabolism and Disposition November 1993, 21 (6) 1064-1069;
  • You have access
    Localization of glutathione conjugation activities toward bromosulfophthalein in perfused rat liver. Studies with the multiple indicator dilution technique.
    Y Zhao, C A Snel, G J Mulder and K S Pang
    Drug Metabolism and Disposition November 1993, 21 (6) 1070-1078;
  • You have access
    Distribution of the anticonvulsant felbamate to cerebrospinal fluid and brain tissue of adult and neonatal rats.
    V E Adusumalli, J K Wichmann, N Kucharczyk and R D Sofia
    Drug Metabolism and Disposition November 1993, 21 (6) 1079-1085;
  • You have access
    Identification of spironolactone metabolites in plasma and target organs of guinea pigs.
    L E Los, A B Coddington, H G Ramjit and H D Colby
    Drug Metabolism and Disposition November 1993, 21 (6) 1086-1090;
  • You have access
    Toxicokinetics of sulfasalazine (salicylazosulfapyridine) and its metabolites in B6C3F1 mice.
    W Zheng, S M Winter, M Mayersohn, J B Bishop and I G Sipes
    Drug Metabolism and Disposition November 1993, 21 (6) 1091-1097;
  • You have access
    In vivo formation of the thiol conjugates of reactive metabolites of 4-ene VPA and its analog 4-pentenoic acid.
    K Kassahun and F Abbott
    Drug Metabolism and Disposition November 1993, 21 (6) 1098-1106;
  • You have access
    Kinetics of nasal carboxylesterase-mediated metabolism of vinyl acetate.
    M S Bogdanffy and M L Taylor
    Drug Metabolism and Disposition November 1993, 21 (6) 1107-1111;
  • You have access
    Biodisposition studies with the acyl-coenzyme A: cholesterol acyltransferase inhibitor 2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide, CI-976.
    T F Woolf, A Black, Y Y Shum, W McNally, H Lee and T Chang
    Drug Metabolism and Disposition November 1993, 21 (6) 1112-1118;
  • You have access
    Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients.
    G K Poon, Y C Chui, R McCague, P E Lłnning, R Feng, M G Rowlands and M Jarman
    Drug Metabolism and Disposition November 1993, 21 (6) 1119-1124;
  • You have access
    Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers.
    C Fernandez, V Maradeix, F Gimenez, A Thuillier and R Farinotti
    Drug Metabolism and Disposition November 1993, 21 (6) 1125-1128;
  • You have access
    Acute phenobarbital administration alters the disposition of acetaminophen metabolites in the rat.
    K L Brouwer
    Drug Metabolism and Disposition November 1993, 21 (6) 1129-1133;
  • You have access
    Absorption, metabolism, and excretion of risperidone in humans.
    G Mannens, M L Huang, W Meuldermans, J Hendrickx, R Woestenborghs and J Heykants
    Drug Metabolism and Disposition November 1993, 21 (6) 1134-1141;
  • You have access
    Pharmacokinetic study of p-chloronitrobenzene in humans suffering from acute poisoning.
    T Yoshida, T Tabuchi and K Andoh
    Drug Metabolism and Disposition November 1993, 21 (6) 1142-1146;
  • You have access
    Formation of a beta-glucuronidase-resistant glucuronide conjugate of digitoxin by dog liver microsomes.
    M C Castle
    Drug Metabolism and Disposition November 1993, 21 (6) 1147-1150;
  • You have access
    Disposition of morphine and its 3- and 6-glucuronide metabolites during morphine infusion in the sheep.
    R W Milne, P A Sloan, C F McLean, L E Mather, R L Nation, W B Runciman, A J Rutten and A A Somogyi
    Drug Metabolism and Disposition November 1993, 21 (6) 1151-1156;
  • You have access
    In vivo and in vitro glucuronidation of the flavonoid diosmetin in rats.
    J A Boutin, F Meunier, P H Lambert, P Hennig, D Bertin, B Serkiz and J P Volland
    Drug Metabolism and Disposition November 1993, 21 (6) 1157-1166;
  • You have access
    Novel cleavage of the 1,2,4-oxadiazole ring in rat metabolism of SM-6586, a dihydropyridine calcium antagonist.
    M Yabuki, F Shono, I Nakatsuka and A Yoshitake
    Drug Metabolism and Disposition November 1993, 21 (6) 1167-1169;
  • You have access
    Inhibitory effects of deuterium substitution on the metabolism of sevoflurane by the rat.
    M T Baker, W C Ronnenberg, J A Ruzicka, C K Chiang and J H Tinker
    Drug Metabolism and Disposition November 1993, 21 (6) 1170-1171;
  • You have access
    Relationship between the terminal disposition half-life and mean residence time in multicompartment models.
    M Mayersohn and R Hamilton
    Drug Metabolism and Disposition November 1993, 21 (6) 1172-1173;
Back to top
PreviousNext

In this issue

Drug Metabolism and Disposition
Vol. 21, Issue 6
1 Nov 1993
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.
  • Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of In Vitro Half-Life Approach and Nonspecific Binding to Microsomes
  • DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS
  • In Vitro-In Vivo Scaling of CYP Kinetic Data Not Consistent with the Classical Michaelis-Menten Model
  • THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics